Project Grant R01HL184442
Award Date 9/1/26
Completion Date 6/30/30
Dollars Obligated $718K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14642, USA
Similar Awards
- Federal Grant Award Summary The University of Rochester received a $226,101 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2027. This award supports a comprehensive reanalysis of existing single-cell RNA sequencing (scRNA-seq) datasets to map the developmental trajectory and cellular fate of pulmonary angioblasts (PACs) and their derived endothelial cell...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,541,783 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate novel roles of the thrombin receptor protease-activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome. The research uses mouse models to examine PAR1's role in button junction formation during lung injury. The work identifies how...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $781,860 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of neutrophils in mediating endothelial regeneration and vascular repair in sepsis and acute respiratory distress syndrome (ARDS). The research addresses ARDS pathology, specifically endothelial barrier injury and increased vascular...
- The National Heart, Lung, and Blood Institute awarded $448,250 to The Research Foundation For The State University Of New York on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger RNA therapy for acute respiratory distress syndrome. The award funds development of an IL-10 mRNA therapeutic delivered via sulfonium lipid nanoparticles, a novel lung-targeting technology designed to suppress...
- The National Heart, Lung, and Blood Institute awarded The Feinstein Institutes for Medical Research $586,866 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the protective role of B-1a cells in acute lung injury and to evaluate a novel therapeutic compound. The project examines the mechanisms by which B-1a cells mitigate acute lung injury and acute respiratory distress syndrome, conditions frequently triggered by sepsis or ischemia-reperfusion...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $670,622 as a Project Grant (R01HL180941) on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the role of endogenous RNA sensing in the amplification of lung injury. The research focuses on how lung infections induce widespread lung vascular endothelial injury through a cycle of endothelial barrier breakdown and inflammatory cell influx. The project...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $917,304 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular and molecular coordination of alveolar regeneration. The award supports research into how epithelial, endothelial, and mesenchymal cells coordinate repair of alveolar structures damaged by infection, environmental toxins, hyperoxia, or barotrauma. The project examines...
- The National Heart, Lung, and Blood Institute awarded the University of Georgia Research Foundation, Inc. $588,284 on August 1, 2026, to investigate long noncoding RNA regulation in complement-mediated endothelial barrier disruption as a potential therapeutic strategy for acute lung injury and acute respiratory distress syndrome. Award R01HL178801 is funded under the Cardiovascular Diseases Research program (CFDA 93.837), a Project Grant. The research addresses the persistent 30–40% mortality...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Washington University $635,247 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of resolution-phase neutrophils in acute respiratory distress syndrome (ARDS) recovery. The project tests the hypothesis that neutrophils activate counter-regulatory mechanisms, including expression of 15-lipoxygenase (15-LO), in lung tissue following acute injury to...